Table I.
Characteristic | Median [range], n (%) | ||||
---|---|---|---|---|---|
Arm A (N= 38) |
Arm B (N= 11) |
Total (N= 49) |
|||
Age, years | 61.5 [24–76] | 56 [23–73] | 58 [23–76] | ||
Male/Female | 20/18 | 5/6 | 25/24 | ||
ECOG Performance Status | |||||
0 | 0 | 1 (9) | 1 (2) | ||
1 | 25 (66) | 5 (45) | 30 (61) | ||
2 | 10 (26) | 5 (45) | 15 (31) | ||
3 | 3 (8) | 0 (0) | 3 (6) | ||
Type of Leukemia | |||||
AML | 30 (79) | 9 (82) | 39 (80) | ||
ALL | 7 (18) | 2 (18) | 9 (18) | ||
CML | 1 (3) | 0 (0) | 1 (2) | ||
Risk Status AML | CG | Mol. abn | CG | Mol. abn | |
Favorable | 0 (0) | 1 (3) | 0 (0) | 0 (0) | 1 (3) |
Intermediate risk | 13 (43) | 0 (0) | 3 (33) | 0 (0) | 16 (41) |
Poor risk | 17 (57) | 0 (0) | 6 (67) | 1 (11) | 23 (59) |
ALL | |||||
B cell | 4 (57) | 0 (0) | 4 (44) | ||
T cell | 3 (43) | 2 (100) | 5 (56) | ||
Prior Stem Cell Transplant | 12 (32) | 6 (55) | 18 (37) | ||
No. of prior therapies | 5 [2–10] | 5 [2–9] | 5 [2–10] | ||
≥3 prior therapies | 33 (87) | 8 (78) | 41 (84) |
Arm A; Daily IV evofosfamide administration, Arm B; continuous evofosfamide administration CG, cytogenetics; Mol. abn, molecular abnormalities